

INDEX

A

Abdomen

- in actinomycosis, Nov. 65
- infection, Nov. 4-18
 - cephalosporins in, July 47-48
 - postoperative, Nov. 7-8
 - therapy, Nov. 16-18
- of wall, Nov. 8
- wound infections, Nov. 7-8
- paracentesis, ascitic fluid during, Sept. 34

Abortion: septic, Nov. 25-26

Abscess

- brain (see Brain abscess)
- epidural, Oct. 48
- gas, Nov. 43-44
- intraperitoneal, Nov. 8-9
- liver, Nov. 14-15
- muscle, Nov. 55
- peritonissillar, Oct. 55-56
- retroperitoneal, Nov. 18-19
- skin, Nov. 37-39
 - anaerobes in, incidence of, Nov. 38
- subcutaneous, Nov. 37-39
 - anaerobes in, incidence of, Nov. 38
- subphrenic, Nov. 8-9

Achilles tendon: necrosis of, Nov. 33

Acidosis: D-lactic, Nov. 76

Acromegaly: and sleep apnea syndrome, May 45-46

- Actinomycosis, Nov. 64-68
 - abdominal form, Nov. 65
 - cervicofacial form, Nov. 64-65
 - diagnosis, Nov. 66-67
 - therapy, Nov. 67-68
 - thoracic form, Nov. 65

Adrenal: anorexia nervosa, June 22

Age: in coronary artery disease, Dec. 20

Aged: drugs causing confusion in, Apr. 53

Airway

- abnormalities, anatomical, May 47-48
- challenges, lung host defenses for, Feb. 8-9
- conducting, and host defense, Feb. 18-19
- normal, microbial flora of, Feb. 19-21
- pharyngeal, in sleep apnea, May 11

Allergic reactions: to

- cephalosporins, July 50-51

Alveolar

macrophage

- chemotactic factors produced by, Feb. 63-66
- culture supernates, pooled, gel filtration of, Feb. 64
- defects contributing to pneumonia, Feb. 66-78
- interplay with polymorphonuclear granulocytes, Feb. 60-63
- spaces, host defenses of, Feb. 55-81

Alzheimer's disease, Apr. 8-69 (See also Dementia syndrome)

- basic mechanisms in, Apr. 35-37
- behavioral support, Apr. 61
- brain function in, Apr. 34
- caring for patients with, Apr. 56-65
- cell loss in, Apr. 28-29
- cellular mechanisms in, Apr. 34-35

INDEX

A

Abdomen

- in actinomycosis, Nov. 65
- infection, Nov. 4-18
 - cephalosporins in, July 47-48
 - postoperative, Nov. 7-8
 - therapy, Nov. 16-18
- of wall, Nov. 8
- wound infections, Nov. 7-8
- paracentesis, ascitic fluid during, Sept. 34

Abortion: septic, Nov. 25-26

Abscess

- brain (see Brain abscess)
- epidural, Oct. 48
- gas, Nov. 43-44
- intraperitoneal, Nov. 8-9
- liver, Nov. 14-15
- muscle, Nov. 55
- peritonissillar, Oct. 55-56
- retroperitoneal, Nov. 18-19
- skin, Nov. 37-39
 - anaerobes in, incidence of, Nov. 38
- subcutaneous, Nov. 37-39
 - anaerobes in, incidence of, Nov. 38
- subphrenic, Nov. 8-9

Achilles tendon: necrosis of, Nov. 33

Acidosis: D-lactic, Nov. 76

Acromegaly: and sleep apnea syndrome, May 45-46

- Actinomycosis, Nov. 64-68
 - abdominal form, Nov. 65
 - cervicofacial form, Nov. 64-65
 - diagnosis, Nov. 66-67
 - therapy, Nov. 67-68
 - thoracic form, Nov. 65

Adrenal: anorexia nervosa, June 22

Age: in coronary artery disease, Dec. 20

Aged: drugs causing confusion in, Apr. 53

Airway

- abnormalities, anatomical, May 47-48
- challenges, lung host defenses for, Feb. 8-9
- conducting, and host defense, Feb. 18-19
- normal, microbial flora of, Feb. 19-21
- pharyngeal, in sleep apnea, May 11

Allergic reactions: to

- cephalosporins, July 50-51

Alveolar

macrophage

- chemotactic factors produced by, Feb. 63-66
- culture supernates, pooled, gel filtration of, Feb. 64
- defects contributing to pneumonia, Feb. 66-78
- interplay with polymorphonuclear granulocytes, Feb. 60-63
- spaces, host defenses of, Feb. 55-81

Alzheimer's disease, Apr. 8-69 (See also Dementia syndrome)

- basic mechanisms in, Apr. 35-37
- behavioral support, Apr. 61
- brain function in, Apr. 34
- caring for patients with, Apr. 56-65
- cell loss in, Apr. 28-29
- cellular mechanisms in, Apr. 34-35

chemical characteristics, Apr. 31-33
 consensus criteria, Apr. 42-43, 44-45
 definition, Apr. 10-14
 changes in terminology, Apr. 12-13
 current usage, Apr. 13-14
 original description, Apr. 10-12
 diagnosis, differential, Apr. 42-54
 earliest manifestations, Apr. 18-19
 electron microscopic studies in, Apr. 30-31
 epidemiology, Apr. 14-17
 ethical concerns, Apr. 64-65
 evaluation, clinical, Apr. 54-56
 gross manifestations, Apr. 25
 hospitalization in, Apr. 62
 lesions of, characteristic, Apr. 25-28
 medical care of, Apr. 56-57
 natural history, Apr. 17-24
 neurofibrillary tangles in, Apr. 27
 pathology, Apr. 24-33
 pathophysiology, Apr. 34-37
 progression rate, Apr. 23-24
 psychotropic medication in, Apr. 57-60
 risk factors for, Apr. 15-17
 social support in, Apr. 62-64
 stages
 late, Apr. 22-23
 middle, Apr. 19-21
 structural damage in, Apr. 34
 subcortical nuclei in, Apr. 29-30
 Amdinocillin, July 41
 Amnionitis, Nov. 27
 Amoxicillin: in anaerobic infection, Oct. 29, 31
 Ampicillin: in anaerobic infection, Oct. 29, 31
 Amyotrophic lateral sclerosis:
 possible viral etiology, Aug. 67-68

Anaerobes
 beta-lactamase-producing, Oct. 31
 incidence as normal flora, Oct. 21
 susceptibility to antimicrobial agents, Oct. 30
 in urine, voided, Nov. 28-30
 Anaerobic bacteria: isolated from blood, distribution of clinically significant, Oct. 39
 Anaerobic culture, Oct. 23-25
 specimen collection, Oct. 23-25
 recommended methods for, Oct. 24
 specimen transport, Oct. 25
 Anaerobic infection, Oct. 8-77, Nov. 4-97
 amoxicillin in, Oct. 29, 31
 ampicillin in, Oct. 29, 31
 antimicrobial therapy, Oct. 28
 azlocillin in, Oct. 31
 beta-lactamase inhibitors in, Oct. 35-36
 carbenicillin in, Oct. 31
 cefoxitin in, Oct. 31-32
 cephalosporins in, Oct. 31-32
 in children, Nov. 88-90
 chloramphenicol in, Oct. 35
 clindamycin in, Oct. 34
 clues to, clinical, Oct. 26
 dosage of drugs in, initial, Oct. 38
 doxycycline in, Oct. 34
 erythromycin in, Oct. 32
 general features, Oct. 25-26
 historical aspects, Oct. 8-11
 host factors that may predispose to development of, Oct. 21
 incidence
 of anaerobes in infection, Oct. 17
 of specific anaerobes in various infections, Oct. 19-20
 infections commonly involving anaerobes, Oct. 15-16
 management, Oct. 27-38
 medical therapy, Oct. 28-38

Anaerobic infection (*cont.*)

- methicillin in, Oct. 31
 - metronidazole in, Oct. 35
 - mezlocillin in, Oct. 31
 - minocycline in, Oct. 34
 - naftillin in, Oct. 31
 - normal flora, Oct. 11-16
 - incidence of various anaerobes as, Oct. 21
 - pathogenesis, Oct. 17-23
 - penicillin in, asoxazolyl, Oct. 31
 - penicillin G in, Oct. 29
 - penicillin V in, Oct. 29, 31
 - piperacillin in, Oct. 31
 - side effects of drugs for, Oct. 33
 - surgical therapy, Oct. 27
 - susceptibility testing and, Oct. 28
 - taxonomy, Oct. 10-11
 - tetracycline in, Oct. 32, 34
 - ticarcillin in, Oct. 31
 - toxicity of drugs for, Oct. 33
- Anaerobic pathogens
- common, Oct. 10
 - important, Oct. 10

Androgen: excess and sleep apnea syndrome, May 46-47

Angina

- in men (*see* Electrocardiography, exercise, in men with angina)
- pain of, classification rule for, Dec. 22
- Vincent's, Oct. 55-56
- in women (*see* Electrocardiography, exercise, in women, with angina)

Ankylosing (*see* Spondylitis, ankylosing)

Anorexia nervosa, June, 9-34

- adrenal in, June 22
- behavior modification in, June 32
- biologic considerations, June 12-13
- body image disturbance in, June 16-17

cardiovascular system in, June 23

cognitive deficits in, June

17-18

diagnosis, June 25-27

diagnostic evaluation for other medical disorders, June 27

endocrine dysfunction in, June 18-23

epidemiologic features, June 10-12

family therapy in, June 33

gastrointestinal system in, June 24

gonadal dysfunction in, June 18-21

growth hormone in, June 22-23

hematologic abnormalities in, June 24

ineffectiveness in, sense of, June 17

insight-oriented therapy of, June 32

management, nutritional/medical, June 29-32

medical features, June 18-25

nutrition in, measurements, June 24-25

outcome, June 33-35

patient with anorexia nervosa, June 15-18

perceptual disturbances in, June 17

pharmacotherapy of, June 32

premorbid psychosocial features, June 13-15

prognosis, June 33-35

prognostic factors in, long-term, June 35

Prognostic Nutritional Index, June 28

psychotherapy of, June 32-33

thyroid in, June 21

treatment, June 27-29

vasopressin in, June 23

weight gain after therapy in, June 34

Antabuse reaction, July 16

- Antianginal drugs: starting in coronary artery disease, Dec. 33
- Antibiotic(s)
penetration into body fluids, July 25
in peritonitis, bacterial, Sept. 36-39
- Antibodies: in chronic virus infection, Aug. 17-18
- Antigens: viral, changes in, Aug. 15-16
- Antimicrobial agents
in anaerobic infection, Oct. 28
in colitis, pseudomembranous, Nov. 70-72
comparison of, Oct. 37
in diarrhea, Nov. 70-72
investigational, July 38-43
microbial susceptibility to, July 39
synopsis, July 42-43
susceptibility of anaerobes to, Oct. 30
- Apnea (*see* Sleep, apnea)
- Appendiceal infections, Nov. 10-11
- Appliances: in sleep apnea syndrome, May 21
- Arrhythmia
with dual-chamber pacing, Mar. 31-37
initiated by dual-chamber pacemaker, Mar. 31-33
pacemakers and, Mar. 29-37
sustained by dual-chamber pacing, Mar. 33-36
with VVI pacemakers, Mar. 30-31
- Arteries (*see* Coronary artery)
- Arteriography: coronary, in coronary artery disease, Dec. 21
- Arthritis
mutilans, Jan. 33
psoriatic, Jan. 39-42
eight types, Jan. 39
reactive, features of, Jan. 36-37
- rheumatoid, contrasted with enthesopathies, Jan. 11
spondylarthritis, seronegative, Jan. 10-17
- Arthropathy: reactive, pattern of disease response, Jan. 15-17
- Ascites
bacterascites, Sept. 7-8
fluid
during abdominal paracentesis, Sept. 34
analysis in spontaneous bacterial peritonitis, Sept. 14, 19-21
protein concentration in, Sept. 18
neutrocytic, culture-negative, Sept. 8-9
predisposing to infection, characteristics of, Sept. 28-33
- Atrial
activity, ventricular pacing synchronized to, Mar. 21
pacing, Mar. 38-39
hemodynamic comparison with ventricular pacing, Mar. 28
refractory period, treatment of pacemaker-mediated tachycardia by, Mar. 35
ventriculoatrial conduction and pacemaker syndrome, Mar. 27-29
- Atrioventricular (*see* AV)
- Autonomic dysfunction: and sleep apnea syndrome, May 42
- AV
block
etiology, Mar. 8-10
pacing in, permanent, Mar. 8-12
pacing in, permanent, indications, Mar. 10-12
intervals and pacemakers, Mar. 46-47
sequential pacing, Mar. 21-24
synchrony restoration with DDD pacing, Mar. 29

AV (cont.)

- universal pacing, Mar. 24-26
- Azlocillin: in anaerobic infection, Oct. 31
- Aztreonam, July 38-40
 - structure, July 40

B

- Back pain (see Pain, back)
- Bacterascites, Sept. 7-8
- Bacteremia, Oct. 38-42
 - anaerobic, portals of entry, Oct. 41
 - spontaneous, Sept. 7
 - urinary tract related, Nov. 30-31

Bacteria

- adherence to respiratory tract mucosa, and colonization, Feb. 21-23
- anaerobic, isolated from blood, distribution of clinically significant, Oct. 39
- inhaled into lungs, clearance of, factors responsible for, Feb. 13
- systemic clearance, and intrahepatic shunting, Sept. 26-28

Bacterial peritonitis (see Peritonitis, bacterial)

Bacterial synergistic gangrene, Nov. 44-45

"Bamboo" spine: in spondylitis, Jan. 14

Bayes' theorem, Dec. 9-10

Behavior modification: in anorexia nervosa, June 32

Behavioral scale: for dementia, Apr. 41

Beta-lactamase

- cephalosporin and, July 11
- inhibitors in anaerobic infection, Oct. 35-36
- producing anaerobes, Oct. 31

Bifascicular block: chronic, permanent pacing in, indications, Mar. 14

Biliary tract infections, Nov. 12-14

Bite wound infections, Nov. 42-43

Block

- AV (see AV, block)
- bifascicular, chronic, permanent pacing in, indications, Mar. 14
- trifascicular, chronic, permanent pacing in, indications, Mar. 14

"Blue bloaters:" vs. "pink puffers," May 37-41

Body image: disturbances in anorexia nervosa, June 16-17

Bone

- infection, Nov. 57-61
 - cephalosporins in, July 48-49
 - involved in osteomyelitis, anaerobic, Nov. 59
- Botulism, Nov. 77-82
 - clinical picture, Nov. 79-80
 - diagnosis, Nov. 80-81
 - epidemiology, Nov. 78-79
 - pathogenesis, Nov. 79
 - therapy, Nov. 81-82

Bowel

- bacterial overgrowth syndromes, Nov. 74-76
- hyperplasia, lymphonodular, with immunoglobulin A deficiency, Nov. 76
- inflammatory bowel disease, Jan. 43-44
 - management, Jan. 44

Bradyarrhythmias: pacing in, indications, Mar. 8-18

Brain abscess, Oct. 44-49

- clinical features, Oct. 45-46
- diagnostic evaluation, Oct. 46-47

- etiologic agents, Oct. 45
- pathogenesis, Oct. 44-45
- therapy, Oct. 47-48

Brain: function in Alzheimer's disease, Apr. 34

Breast infection, Nov. 32-33

Breathing

- in asymptomatic subjects, May 25-30
- epidemiology, May 25-27
- during sleep, baseline changes, May 30-31
- Bronchitis: chronic, and secretory IgA, Feb. 23-28
- Bulimia, June 35-45
 - binge-purge cycle in, June 38-39
 - development of coping strategies, June 43
 - diagnosis, June 41
 - epidemiologic features, June 36-38
 - medical features, June 40
 - outcome, June 44-45
 - pathogenesis, June 39-40
 - patient with bulimia, June 37-38
 - pharmacotherapy, June 43-44
 - premonitory features, June 37
 - prognosis, June 44-45
 - psychosocial features, June 36-38
 - psychotherapy in, June 42-43
 - self-monitoring in, June 43-43
 - treatment, June 41-45
- Burn wound infections, Nov. 47
- Bursa: subacromial, pus from, Nov. 33
- Buttock: infections of, Nov. 32
- Bypass
 - enteropathy, Nov. 75
 - gastric, illustration, May 19
 - ileal, for obesity, Nov. 75

C

Calcification

- at entheses in ankylosing spondylitis, Jan. 9
- in spondylitis, advanced, Jan. 14
- Cancrum oris, Nov. 46
- Carbenicillin
 - in anaerobic infection, Oct. 31
 - structure, July 14
- Cardiac (see Heart)

Cardiovascular system: in

- anorexia nervosa, June 23
- Care: and Alzheimer's disease, Apr. 56-65
- Cefoperazone: structure, July 15
- Cefoxitin, July 32-34
 - in anaerobic infection, Oct. 31-32
 - clinical correlates, July 33-34
 - structure, July 17
- Ceftazidime, July 38
- Cefuroxime: structure, July 14
- Cell(s)
 - associated viral infections, Aug. 16-17
 - loss in Alzheimer's disease, Apr. 28-29
 - mediated immunity, macrophages lacking, Feb. 75-78
 - membranes, failure of virus to express viral antigens on, Aug. 16
 - respiratory, forming rosettes with IgG subclass-erythrocyte complexes, Feb. 42
- Cellulitis, Nov. 35
 - anaerobic, Nov. 43-44
 - clostridial, Nov. 43-44
 - orbital, Oct. 52-53
- Central nervous system infections, Oct. 44-49
 - viral (see Virus infections, of central nervous system)
- Cephalosporins, July 7-60
 - in abdominal infection, July 47-48
 - action mechanism, July 9-12
 - activity against *Pseudomonas*, July 35-38
 - clinical correlates, July 35-38
 - administration, July 17-23
 - adverse effects, July 50-52
 - allergic reactions to, July 50-51
 - in anaerobic infection, Oct. 31-32
 - available in 1985, July 10
 - in bone infections, July 48-49

Cephalosporins (*cont.*)
 cost, July 36-37, 53-54
 desacetylation reaction, July 28
 disulfiram reaction, July 16
 efficacy, July 52-53
 elimination, July 27-28
 ethyl alcohol metabolism and,
 July 16
 generations
 definition of, July 28-38
 first-generation, July 29-31
 first-generation, clinical
 correlates, July 31
 second-generation, July 31-32
 third-generation, July 34
 glossary for, July 7-8
 for granulocytopenic patient,
 febrile, July 49
 half-life, July 8
 trends in, July 19
 in joint infections, July 48-49
 marketed in U.S., July 9
 MBC, July 8
 in meningitis, July 46-47
 MIC, July 8
 microbes susceptible to, July
 26-27
 nucleus of, July 12-16
 oral
 cost, July 37
 pharmacokinetics, July 18
 parenteral
 cost, July 36
 pharmacokinetics, July 20-21
 penetration into body fluids,
 July 24-27
 pharmacokinetics, July 17-28
 in pneumonia, July 44-46
 protein binding, July 23-24
 in renal failure, dosing interval,
 July 23
 R-1 side chains, July 7
 R1 substituent, July 13
 R-2 side chains, July 8
 R2 substituent, July 14-16
 safety, July 53
 selection criteria for, July 52-54
 in skin infections, July 48

in soft tissue infections, July 48
 structure, July 13
 structure-function relationships,
 July 12-17
 for surgical prophylaxis, July
 49-50
 therapeutic uses, July 43-50
 toxic reactions to, July 51-52
 in urinary tract infections, July
 46
 Cephameycins, July 16-17
 Chemotactic factors: produced by
 alveolar macrophages, Feb.
 63-66
 Chest
 in actinomycosis, Nov. 65
 expansion in ankylosing
 spondylitis, Jan. 24-25
 pain (*see* Pain, chest)
 Children: anaerobic infections of,
 Nov. 88-90
 Chloramphenicol: in anaerobic
 infection, Oct. 35
 Cholangitis: acute ascending, Nov.
 13-14
 Cholecystitis: acute, Nov. 12-13
 Ciliary
 clearance, Feb. 28-34
 defect, case review, Feb. 49-52
 dysfunction, Feb. 29-34
 Ciliotoxic infections, Feb. 32-34
 Cilium: cross section of, Feb. 29
 Clavulanate, July 41-42
 Clavulanic acid: structure, July 42
 Clindamycin: in anaerobic
 infection, Oct. 34
 Clostridial
 cellulitis, Nov. 43-44
 enteric diseases, Nov. 68-74
 fasciitis, Nov. 50
 food poisoning, Nov. 69
 myonecrosis, Nov. 50-53
 CNS (*see* Central nervous system)
 Cognitive deficits: in anorexia
 nervosa, June 17-18
 Cognitive impairment: global, in
 dementia syndrome, Apr.
 39-42

- Colitis: pseudomembranous, antimicrobial agents in, Nov. 70-72
- Complement-mediated clearance: of microbes from lower respiratory tract, Feb. 73-74
- Confusion: drugs causing, in aged, Apr. 53
- Conjunctivitis, Oct. 50-51
- Cordotomy: and sleep apnea syndrome, May 43
- Cornea: infections of, Oct. 51
- Coronary arteriography: in coronary artery disease, Dec. 21
- Coronary artery disease, Dec. 7-71
 - antianginal medication in, starting, Dec. 33
 - complication rates of detection and treatment, Dec. 51-52
 - counsel in, Dec. 33
 - detection, complication rates of, Dec. 51-52
 - diagnostic tests
 - effect on patient management, Dec. 33-34
 - results, useful, Dec. 33-34
 - exercise predictors, Dec. 47
 - exercise testing in, Dec. 7-71
 - pretest risk, estimation of, Dec. 17-23
 - exercise testing in prediction of, Dec. 52-54
 - prevalence, Dec. 18
 - estimation, clinical prediction rule for, Dec. 21
 - probability, Dec. 34
 - prognosis, Dec. 44-48
 - prognostication, Dec. 33
 - reassurance in, Dec. 33
 - risk in asymptomatic persons, Dec. 50-51
 - screening, Dec. 49-57
 - cost-effectiveness of, Dec. 56
 - effect of cardiac risk factors on yield of, Dec. 54-56
 - effect of prior screening tests, Dec. 56
 - exercise ECG for, Dec. 53
 - rationale for, Dec. 49-50
 - severity
 - chest pain, age and gender in, Dec. 20
 - relationship with survival predictors, Dec. 47-48
 - ST-segment response to exercise as predictor of, Dec. 32
 - survival predictors, relationship with coronary artery disease severity, Dec. 47-48
 - treatment
 - complication rates of, Dec. 51-52
 - effect of, in asymptomatic persons, Dec. 51
 - effect on outcome, Dec. 23-26
- Coronary artery stenosis, left main
 - detection of, Dec. 58-64
 - by exercise tests, Dec. 59-62
 - rationale for, Dec. 58
 - exercise test prediction of, Dec. 61-62
 - myocardial scintiscan in, Dec. 61
 - pretest risk, estimation of, Dec. 58-59
- Cost
 - of coronary artery disease screening, Dec. 56
 - of exercise ECG, Dec. 13
 - of myocardial scintigraphy, stress thallium 201, Dec. 14
- Counsel: in coronary artery disease, Dec. 33
- Creutzfeldt-Jakob disease, Aug. 52-58
 - clinical disease, Aug. 54-56
 - diagnosis, Aug. 57-58
 - epidemiology, Aug. 52-54
 - laboratory findings, Aug. 56
 - pathology, Aug. 56-57
 - precautions in care of patients, Aug. 65-66
 - prognosis, Aug. 65
 - subtypes, clinical, Aug. 55-56

Creutzfeldt-Jakob disease (*cont.*)
 treatment, Aug. 65
 Culture (*see* Anaerobic culture)
 Cutaneous (*see* Skin)
 Cyst
 inclusion, infected, Nov. 36
 pilonidal sinus, infected, Nov.
 46-47
 sebaceous, infected, Nov. 36
 Cystic fibrosis, Feb. 34-38
 case review, Feb. 45-49

D

Death: sudden infant death
 syndrome and sleep apnea,
 May 50-52
 Decubitus ulcer: infected, Nov.
 41-42
 Dementia
 behavioral scale for, Apr. 41
 "the bits" causing, Apr. 53-54
 depression and, Apr. 48-49
 evaluation for, Apr. 46
 ischemic score and, modified,
 Apr. 47
 mixed, Apr. 48
 presenile, possible viral etiology,
 Aug. 68
 stroke causing, Apr. 43-47
 syndrome
 (*See also* Alzheimer's disease)
 degenerative diseases causing,
 Apr. 49-50
 diagnosis, Apr. 37-42
 diseases causing, Apr. 51
 epidemiology, Apr. 14-15
 global cognitive impairment
 in, Apr. 39-42
 impairment duration, Apr. 38
 mental status tests and, Apr.
 40
 sensorium and, clear, Apr. 38
 systemic illnesses causing, Apr.
 50-52
 toxic drug reactions and, Apr.
 52-53
 Dental infections, Oct. 57-59

Depression: and dementia, Apr.
 48-49
 Desacetylation reaction, July 28
 Desaturation (*see* Oxygen,
 desaturation)
 Diabetes mellitus: fetid foot of,
 Nov. 39-41
 Diarrhea: antimicrobial agents in,
 Nov. 70-72
 Disulfiram reaction, July 16
 Diverticulitis, Nov. 11-12
 D-lactic acidosis, Nov. 76
 Doxycycline: in anaerobic
 infection, Oct. 34
 Drug(s)
 in anaerobic infection
 side effects of, Oct. 33
 toxicity of, Oct. 33
 antiangina, starting in coronary
 artery disease, Dec. 33
 antimicrobial (*see* Antimicrobial
 agents)
 confusion in aged due to, Apr. 53
 in lung disease, chronic
 obstructive, May 40-41
 metabolizing, Nov. 77
 psychotropic, in Alzheimer's
 disease, Apr. 57-60
 in sleep apnea, May 19-21
 toxic reactions causing dementia
 syndrome, Apr. 52-53
 Duodenum: infections related to,
 Nov. 16
 Dystrophy: myotonic, and sleep
 apnea syndrome, May 43

E

Echovirus (*see*
 Meningoencephalitis,
 Echovirus)
 Elderly: drugs causing confusion
 in, Apr. 53
 Electrocardiography
 exercise, Dec. 10-13
 for coronary artery disease
 screening, Dec. 53
 in coronary artery stenosis,
 left main, Dec. 59-60

- cost of, Dec. 13
- error in, sources of, Dec. 12
- false-negative results, Dec. 12
- false-positive results, Dec. 12
- in men, Dec. 27-33
- in men with angina, Dec. 37-41
- in men with angina, effect of tests on outcomes, Dec. 39, 40-41
- in men with angina, negative results, Dec. 39, 40
- in men with angina, positive results, Dec. 38-39, 40
- in men with angina, results that imply diagnostic certainty, Dec. 38
- in men with nonanginal chest pain, Dec. 35-37
- in men with nonanginal chest pain, negative results, Dec. 35-36
- in men with nonanginal chest pain, positive results, Dec. 35
- in men, outcomes, clinical, Dec. 37
- in men, test results, Dec. 37
- with myocardial scintiscan, Dec. 29-30
- performance, effect of history and gender on, Dec. 27-28
- protocol, Dec. 10-12
- stress, in men, interpretation, Dec. 36
- stress, in men, interpretation of, ST-segment depression in, Dec. 37
- stress, with myocardial scintiscan, interpretation, Dec. 35
- stress, test performance in chest pain, Dec. 28
- test performance of, Dec. 31
- in women, Dec. 27-33, 41-44
- in women, with angina, atypical, effect of tests on clinical outcome, Dec. 43

- in women, with angina, atypical, negative results, Dec. 43
- in women, with angina, atypical, positive results, Dec. 42-43
- in women, with angina, typical, Dec. 43-44
- in women, with angina, typical, effect of testing on clinical outcomes, Dec. 44
- in women, with angina, typical, negative results, Dec. 44
- in women, with angina, typical positive results, Dec. 43
- in women, chest pain, nonanginal, Dec. 41-42
- in women, chest pain, nonanginal, negative results, Dec. 42
- in women, chest pain, nonanginal, positive results, Dec. 41-42
- in women, chest pain, nonanginal, test results and clinical outcomes, Dec. 42
- in women, interpretation, Dec. 41-44
- in women, selection, Dec. 41-44
- Electron microscopy: in Alzheimer's disease, Apr. 30-31
- Empyema: subdural, Oct. 48
- Encephalitis: and sleep apnea syndrome, May 44
- Encephalopathy: spongiform, pathogenesis, Aug. 59-61
- Endocarditis, Oct. 42-44
- Endocrine disorders, and sleep apnea syndrome, May 44-47
- dysfunction in anorexia nervosa, June 18-23
- Endophthalmitis, Oct. 51-52
- Enteric diseases: clostridial, Nov. 68-84

Enteritis necroticans, Nov. 69-70
 Enterocolitis: necrotizing, in newborn, Nov. 74
 Enteropathy: bypass, Nov. 75
 Entthesis, Jan. 7
 calcification and fusion at, in ankylosing spondylitis, Jan. 9
 Enthesopathy, Jan. 7-46
 contrasted with rheumatoid arthritis, Jan. 11
 Epidural abscess, Oct. 48
 Erythrocyte: IgG subclass-erythrocyte complexes forming rosettes with respiratory cells, Feb. 42
 Erythromycin: in anaerobic infection, Oct. 32
Escherichia coli: opsonic activity of, Sept. 32
 Ethyl alcohol: metabolism of, and cephalosporins, July 16
 Exercise
 capacity, relationship with ST-segment response, Dec. 30-32
 ECG (see Electrocardiography, exercise)
 myocardial scintigraphy during, thallium 201, Dec. 29
 predictors in coronary artery disease, Dec. 47
 in spondylitis, ankylosing, Jan. 28-29
 ST-segment response to, as predictor of coronary artery disease, Dec. 32
 Exercise testing, Dec. 7-71
 in chest pain, Dec. 16-44
 in coronary artery disease, Dec. 7-71
 prediction, Dec. 52-54
 pretest risk, estimation of, Dec. 17-23
 decision criteria for obtaining, Dec. 32-33
 definitions, Dec. 8-10
 evaluation of, Dec. 14-16

in men
 interpretation of, Dec. 34-41
 selection, Dec. 34-41
 risk of, Dec. 12-13
 sensitivity, Dec. 26-27
 specificity of, Dec. 26-27
 Eyelid infections, Oct. 50

F

Face: in actinomycosis, Nov. 64-65
 False-negative rate, Dec. 9
 in exercise ECG, Dec. 12
 in myocardial scintigraphy, stress thallium 201, Dec. 14
 False-positive rate, Dec. 9
 in exercise ECG, Dec. 12
 in myocardial scintigraphy, stress thallium 201, Dec. 14
 Family therapy: in anorexia nervosa, June 33
 Fascia: infections of, Nov. 48-50
 Fasciitis: clostridial, Nov. 50
 Febrile granulocytopenic patient: cephalosporins for, July 49
 Fibrosis, cystic, Feb. 34-38
 case review, Feb. 45-49
 Flora, normal, Oct. 11-16
 incidence of various anaerobes as, Oct. 21
 Food poisoning: clostridial, Nov. 69
 Foot: fetid, of diabetes, Nov. 39-41
 Forestier's sign: in ankylosing spondylitis, Jan. 25-26
 Fournier's gangrene, Nov. 49-50

G

Gallbladder infections, Nov. 12-14
 Gangrene
 bacterial synergistic, Nov. 44-45
 Fournier's Nov. 49-50
 gas, Nov. 50-53
 vascular, infected, Nov. 55
 Gas
 abscess, Nov. 43-44
 exchange, during sleep, May 32

-forming soft tissue infection,
Nov. 56
gangrene, Nov. 50-53
in wound, evaluation of, Nov.
55-57
Gastric (*see* Stomach)
Gastrointestinal system: in
anorexia nervosa, June 24
Gender
in coronary artery disease, Dec.
20
effect on exercise
electrocardiography, Dec.
27-28
Genetics: of HLA-B27, Jan. 7
Genital tract infection, female,
Nov. 19-27
anaerobes involved in, Nov. 20
Genitalia
diseases of, Nov. 31-32
external, infections of, Nov.
21-22
Gertsman-Sträussler syndrome,
Aug. 58-59
Gonadal dysfunction: in anorexia
nervosa, June 18-21
Granulocytes: polymorphonuclear,
interplay with alveolar
macrophages, Feb. 60-63
Granulocytopenic patient: febrile,
cephalosporins for, July 49
Groin: infections of, Nov. 32
Growth hormone: in anorexia
nervosa, June 22-23
Gynecologic infection:
postoperative, Nov. 24-25

H

Head: infections of, Oct. 53-57, 60
Heart
in anorexia nervosa, June 23
pacemakers (*see* Pacemakers)
Hematologic abnormalities: in
anorexia nervosa, June 24
Hemorrhage: and
hypoprothrombinemia, Nov.
77
Herman's syndrome, Nov. 76-77

Hidradenitis suppurativa, Nov.
36-37
HLA-B27
frequency of, Jan. 15
genetics of, Jan. 7
in spondylitis, seronegative, Jan.
14-15
test, in ankylosing spondylitis,
Jan. 22-23
Hormone: growth, in anorexia
nervosa, June 22-23
Hospitalization: during
Alzheimer's disease, Apr. 62
Host defense
airways and, conducting, Feb.
18-19
of alveolar spaces, Feb. 55-81
deficiency syndromes, adult, Feb.
43-55
evaluation, Feb. 43-55
presentation, clinical, Feb.
43-55
lung, Feb. 11-55
for airway challenges, Feb.
8-9
mechanisms, deficiencies in, and
respiratory infections, Feb.
6-98
nose and, Feb. 14-17
oropharynx and, Feb. 14-17
Hyperplasia: lymphonodular, of
bowel, with immunoglobulin
A deficiency, Nov. 76
Hypogammaglobulinemia
acquired, case review, Feb.
52-55
with meningoencephalitis (*see*
meningoencephalitis,
Echovirus, with
hypogammaglobulinemia)
Hypoprothrombinemia: with
hemorrhage, Nov. 77
Hypothyroidism: and sleep apnea
syndrome, May 44-45

I

Ig (*see* Immunoglobulin)
Ileal bypass: for obesity, Nov. 75

Imaging: liver-spleen, Sept. 29
 Imipenem, July 40-41
 structure, July 41
 Immune opsonins: availability of,
 Feb. 69-70
 Immunity: cell-mediated,
 macrophages lacking, Feb.
 75-78
 Immunodeficiency: and viruses,
 Aug. 18
 Immunoglobulin
 A
 deficiency, and bowel
 hyperplasia, Nov. 76
 secretory, and chronic
 bronchitis, Feb. 23-28

G
 dysfunction, Feb. 38-43
 subclass-erythrocyte
 complexes, forming rosettes
 with respiratory cells, Feb.
 42
 Inclusion cyst: infected, Nov. 36
 Indocyanine green, Sept. 28
 Insight-oriented therapy: in
 anorexia nervosa, June 32
 Inspiration: negative pressure of,
 and pharynx, May 13
 Intestine: in anorexia nervosa,
 June 24
 Intra-abdominal infection (*see*
 Abdominal infection)
 Intrahepatic shunting: and
 systemic clearance of
 bacteria, Sept. 26-28
 Intraperitoneal abscess, Nov. 8-9
 Intrauterine devices: infections
 associated with, Nov. 24
 Intraventricular conduction
 abnormalities: chronic,
 permanent pacing in, Mar.
 12-14
 Ischemic score: modified, and
 dementia, Apr. 47

J

Joint infection, Nov. 62-64
 cephalosporins in, July 48-49

K

Kidney failure: cephalosporins in,
 dosing interval, July 23
 Kuru, Aug. 48-52
 clinical disease, Aug. 50-51
 diagnosis, Aug. 52
 epidemiology, Aug. 49-50
 laboratory findings, Aug. 51
 pathology, Aug. 51-52
 prognosis, Aug. 65
 treatment, Aug. 65
 Kyphoscoliosis: and sleep apnea
 syndrome, May 48-49

L

Lacrimal apparatus infection, Oct.
 51
 Leukoencephalopathy, progressive
 multifocal, Aug. 39-48
 clinical syndrome, Aug. 41-42
 diagnosis, Aug. 45-46
 epidemiology, Aug. 39-41
 laboratory findings, Aug. 42-43
 pathology, Aug. 43-45
 treatment, Aug. 47-48
 viruses isolated from brain
 tissue, Aug. 46-47
 Likelihood ratio, Dec. 9
 Liver
 abscess, Nov. 14-15
 disease and bacterial peritonitis,
 Sept. 11-12
 intrahepatic shunting and
 systemic clearance of
 bacteria, Sept. 26-28
 -spleen imaging, Sept. 29
 Lung
 bacteria inhaled into, clearance
 of, factors responsible for,
 Feb. 13
 disease, chronic obstructive, May
 30-41
 drug therapy, May 40-41
 oxygen therapy, May 39-40
 therapy, May 39
 ventilator therapy, May 39

- disease, and sleep apnea syndrome, May 49-50
- host defenses, Feb. 11-55
 - for airway challenges, Feb. 8-9
- infection (*see* Pleuropulmonary infection)
- inflammatory response, and PMNs, Feb. 78-81
- Lymph nodes: suppurative involvement by anaerobes, Nov. 33
- Lymphonodular hyperplasia: of bowel with immunoglobulin A deficiency, Nov. 76

M

- Macrophage
 - alveolar (*see* Alveolar, macrophage)
 - intracellular microbes contained by, Feb. 75
 - lacking cellular activation and cell-mediated immunity, Feb. 75-78
- Mastoiditis, Oct. 54
- Measles virus: isolated from subacute sclerosing panencephalitis, Aug. 28-30
- Mediastinitis, Oct. 68
- Medication (*see* Drugs)
- Meleney's ulcer, Nov. 47
- Meningitis, Oct. 48-50
- cephalosporins in, July 46-47
- Meningoencephalitis, Echovirus, with
 - hypogammaglobulinemia, Aug. 36-39
 - clinical syndrome, Aug. 36-37
 - diagnosis, Aug. 38
- Echoviruses isolated from meningoencephalitis, Aug. 38
- epidemiology, Aug. 36
- laboratory, Aug. 37-38
- pathology, Aug. 38
- treatment, Aug. 39
- Mental status tests: and dementia syndrome, Apr. 40
- Metabolizing drugs, Nov. 77
- Methicillin: in anaerobic infection, Oct. 31
- Metronidazole: in anaerobic infection, Oct. 35
- Mezlocillin: in anaerobic infection, Oct. 31
- Microbial flora: of normal airways, Feb. 19-21
- Microscopy: electron, in Alzheimer's disease, Apr. 30-31
- Monitoring: self-monitoring in bulimia, June 42-43
- Monocytes: intracellular microbes contained by, Feb. 75
- Mouth: infections of, Oct. 57-59
- Moxalactam: structure, July 14, 17
- Multiple sclerosis: possible viral etiology, Aug. 66-67
- Muscle
 - abscess, Nov. 55
 - infection of, Nov. 33-57
 - anaerobic, categories of, Nov. 34
- Mutants: viral, temperature-sensitive, Aug. 17
- Myocardium
 - infarction, acute, permanent pacing in, Mar. 14-16
 - infection, Oct. 69
 - scintigraphy, stress thallium 201, Dec. 13-14
 - cost, Dec. 14
 - error in, sources of, Dec. 14
 - false-negative results, Dec. 14
 - false-positive results, Dec. 14
 - protocol, Dec. 13-14
 - risks, Dec. 14
 - scintiscan
 - in coronary artery stenosis, left main, Dec. 61
 - with exercise ECG, Dec. 29-30
 - thallium 201, Dec. 29, 35

- Myonecrosis
 - anaerobic streptococcal, Nov. 53-54
 - clostridial, Nov. 50-53
 - synergistic nonclostridial, Nov. 54-55
- Myotonic dystrophy: and sleep apnea syndrome, May 43

N

- Nafcillin: in anaerobic infection, Oct. 31
- Neck
 - in actinomycosis, Nov. 64-65
 - infection, Oct. 53-57, 60
- Neckspace infection: deep, Oct. 56-57
- Necrosis of Achilles tendon, Nov. 33
- Necrotizing enterocolitis: in newborn, Nov. 74
- Neonatal (see Newborn)
- Nervous system (see Central nervous system)
- Neurofibrillary tangles: in brain, conditions with, Apr. 27
- Neurologic diseases
 - with possible viral etiology, Aug. 66-68
 - sleep apnea syndrome and, May 41-44
- Newborn
 - enterocolitis, necrotizing, Nov. 74
 - infections of, Nov. 89-90
- Noma, Nov. 46
- Nose: and host defenses, Feb. 14-17
- Nutrition
 - management in anorexia nervosa, June 29-32
 - measurements in anorexia nervosa, June 24-25
 - Prognostic Nutritional Index, June 28

O

- Obesity: ileal bypass for, Nov. 75
- Ophthalmic infections, Oct. 49-53

- Opsonic activity: of, *Escherichia coli*, Sept. 32

- Opsonins
 - immune, availability of, Feb. 69-70
 - nonimmune, role of, Feb. 70-73

- Oral infections, Oct. 57-59
- Orbital cellulitis, Oct. 52-53
- Oropharynx: and host defenses, Feb. 14-17

- Osteomyelitis
 - anaerobes recovered from, types of, Nov. 59
 - anaerobic, bones involved in, Nov. 59

- Otitis media, Oct. 54

- Oxygen
 - desaturation, episodic, May 31-34
 - desaturation, nocturnal, clinical effects, May 34-37
 - cardiovascular, May 35-37
 - hematologic, May 37
 - neuropsychological, May 34-35
 - therapy in COPD, May 39-40

- Oxygenation: during sleep, baseline changes, May 30-31

- Oxyhemoglobin dissociation curve, May 30

P

- Pacemakers, Mar. 6-52
 - AAI, Mar. 19-20
 - arrhythmia and, Mar. 29-37
 - AV intervals and, Mar. 46-47
 - classification, international, Mar. 19
 - DDD, Mar. 40-41
 - dual-chamber, arrhythmia initiated by, Mar. 31-33
- DVI, Mar. 40
 - committed, Mar. 22-23
 - noncommitted, Mar. 23-24
- follow-up, Mar. 47-49

- mediated tachycardia,
 - treatment by extension of atrial refractory period, Mar. 35
- output indices, Mar. 43-44
- permanent, choice of, Mar. 38-41
- programmable functions, Mar. 42-47
- rate, Mar. 42-43
- refractory period
 - programmability, Mar. 46
- sensitivity, Mar. 44-46
- single-chamber, Mar. 19-20
- surveillance, Mar. 47-49
- syndrome, and ventriculoatrial conduction, Mar. 27-29
- types, Mar. 18-26
- VVI, Mar. 19-20
 - arrhythmia with, Mar. 30-31
- Wenckebach response to, Mar. 37
- Pacing
 - atrial, Mar. 38-39
 - hemodynamic comparison with ventricular pacing, Mar. 28
 - AV sequential, Mar. 21-24
 - AV universal, Mar. 24-26
 - in bradyarrhythmias, indications, Mar. 8-18
 - DDD, Mar. 24-26, 34
 - AV synchrony restoration with, Mar. 29
 - with failure to sense P waves, Mar. 45
 - dual-chamber, Mar. 40-41
 - arrhythmia with, Mar. 31-37
 - arrhythmia sustained by, Mar. 33-36
- DVI
 - committed, Mar. 23
 - committed, ventricular repetitive response produced by, Mar. 32
 - noncommitted, Mar. 24
- permanent
 - in AV block, Mar. 8-12
 - in AV block, indications, Mar. 10-12
 - in bifascicular block, chronic, indications, Mar. 14
 - in intraventricular conduction abnormalities, chronic, Mar. 12-14
 - in myocardial infarction, acute, Mar. 14-16
 - in sick sinus syndrome and variants, indications, Mar. 18
 - in trifascicular block, chronic, indications, Mar. 14
- physiologic
 - special considerations, Mar. 26-37
 - upper rate response, features of, Mar. 36-37
- single-chamber, Mar. 19-20
- ventricular, Mar. 39-40
 - hemodynamic comparison with atrial pacing, Mar. 28
 - synchronized to atrial activity, Mar. 21
- Pain
 - of angina, classification rule for, Dec. 22
- back
 - in ankylosing spondylitis, five characteristics of, Jan. 21
 - differentiating mechanical back pain from inflammatory pain, Jan. 21
- chest
 - in coronary artery disease, Dec. 20
 - ECG test performance in, Dec. 28
 - exercise testing in, Dec. 16-44
- Pancreas: infections of, Nov. 15-16
- Panencephalitis
 - rubella, progressive, Aug. 31-36
 - clinical syndrome, Aug. 31-32
 - diagnosis, Aug. 35
 - epidemiology, Aug. 31
 - laboratory findings, Aug. 32-33
 - pathology, Aug. 33-35
 - rubella virus isolates from, Aug. 35-36

- Panencephalitis (cont.)**
 treatment, Aug. 36
 subacute sclerosing, Aug. 22-31
 clinical disease, Aug. 23-25
 diagnosis, Aug. 28
 epidemiology, Aug. 22-23
 laboratory findings, Aug. 25-27
 measles virus isolated from, Aug. 28-30
 pathology, Aug. 27-28
 second virus hypothesis, Aug. 30
 treatment, Aug. 30-31
- Paracentesis:** abdominal, ascitic fluid during, Sept. 34
- Parkinson's disease:** possible viral etiology, Aug. 67
- Paronychia**, Nov. 37
- Pelvic inflammatory disease**, Nov. 22-23
- Penicillin**
 -binding proteins, July 7, 11
 G, in anaerobic infection, Oct. 29
 isoxazolyl, m anaerobic infection, Oct. 31
 structure, July 13
 V, in anaerobic infection, Oct. 29, 31
- Pericarditis**, Oct. 69
- Perineal infection**, Nov. 19
- Perirectal infection**, Nov. 19
- Peritoneal abscess**, Nov. 8-9
- Peritonitis**, Nov. 9-10
- Peritonitis, bacterial**
 definition, Sept. 6-10
 historical perspective, Sept. 6-10
 secondary, Sept. 9-10
 spontaneous, Sept. 6-48
 antibiotics in, Sept. 36-39
 ascites predisposing to infection, characteristics of, Sept. 28-33
 ascitic fluid analysis in, Sept. 14-15, 19-21
 bacterial entrance mode to peritoneal cavity, Sept. 24-26
 bacterial source in, Sept. 24-26
 case reports, Sept. 40-45
 clinical presentation, Sept. 12-14
 clinical problems contributing to death, Sept. 21
 clinical syndrome, Sept. 10-24
 diagnosis, Sept. 33-36
 infectious involvement other than ascites and blood, Sept. 15-16
 liver disease and, Sept. 11-12
 onset relative to time of hospital admission, Sept. 13
 organism, Sept. 14-15
 pathogenesis, Sept. 24-33
 phagocytic activity and, reticuloendothelial system, Sept. 30
 predisposing factors, Sept. 16-19
 prevention, Sept. 39
 prognostic factors, Sept. 23-24
 recurrence, Sept. 15-16
 survival in, Sept. 21-23
 therapy, Sept. 36-39
- Peritonsillar abscess**, Oct. 55-56
- Phagocytic activity:**
 reticuloendothelial system, and bacterial peritonitis, Sept. 30
- Pharmacotherapy**
 in anorexia nervosa, June 32
 in bulimia, June 43-44
- Pharynx**
 collapse, beneficial effect of applied positive pressure to, May 22
 CT of, May 12
 negative pressure of normal inspiration and, May 13
- Pickwickian syndrome:**
 relationship with sleep apnea syndrome, May 23-24
- Pilonidal sinus:** infected, Nov. 46-47
- "Pink puffers:"** vs. "blue bloaters," May 37-41

- Piperacillin
in anaerobic infection, Oct. 31
structure, July 15
- Pleuropulmonary infection, Oct.
59-68
anaerobes encountered in, major,
Oct. 63
clinical picture, Oct. 64-65
diagnosis, Oct. 65-66
etiologic agents, Oct. 63-64
history, Oct. 60-61
pathogenesis, Oct. 61-62
therapy, Oct. 66-68
- PMNs: and lung inflammatory
response, Feb. 78-81
- Pneumatosis cystoides intestinalis,
Nov. 75
- Pneumonia
alveolar macrophage defects
contributing to, Feb. 66-78
cephalosporins for, July 44-46
- Poisoning: clostridial food, Nov. 69
- Poliomyelitis: and sleep apnea
syndrome, May 42-43
- Polyarthropathy: juvenile chronic,
Jan. 42-43
- Polymorphonuclear granulocytes:
interplay with alveolar
macrophages, Feb. 60-63
- Polysomnography: in sleep apnea
syndrome, May 8-9
- Porins, July 7, 11
- Postpartum infections, Nov. 26-27
- Prevalence, Dec. 8
relationship with probability,
Dec. 10
- Probability, Dec. 8
posttest, Dec. 8
pretest, Dec. 8
relationship with prevalence,
Dec. 10
- Prognostic Nutritional Index, June
28
- Prostate: cultures, Nov. 30
- Protein
binding and cephalosporins, July
23-24
concentration in ascitic fluid in
peritonitis, Sept. 18
penicillin-binding, July 7, 11
- Pseudomonas*, cephalosporin
activity against, July 35-38
clinical correlates, July 35-38
- Psoriatic arthritis, Jan. 39-42
eight types, Jan. 39
- Psychotherapy
in anorexia nervosa, June 32-33
in bulimia, June 42-43
- Psychotropic drugs: in Alzheimer's
disease, Apr. 57-60
- Pulmonary (see Pleuropulmonary
infection)
- Pus: from subacromial bursa, Nov.
33
- P waves: DDD pacing with failure
to sense, Mar. 45
- Pyoderma, Nov. 37
- Pyogenic infections: pathogenesis,
Oct. 17-22
- Pyometra, Nov. 24
- R
- Radiography: in ankylosing
spondylitis, Jan. 23
- Rectum: infections of, Nov. 19
- Reiter's syndrome, Jan. 32-39
- Respiratory
cells forming rosettes with IgG
subclass-erythrocyte
complexes, Feb. 42
infections, and host defense
mechanism deficiencies, Feb.
6-98
tract mucosa, bacterial
adherence to, and
colonization, Feb. 21-23
- Reticuloendothelial system
phagocytic activity: and
bacterial peritonitis, Sept.
30
- Retroperitoneal abscess. Nov.
18-19
- Rheumatoid arthritis: contrasted
with enthesopathies, Jan. 11
- Rieter's syndrome
diagnosis, Jan. 34-35
history, clinical, Jan. 35-36

Rieter's syndrome (*cont.*)
management, Jan. 37-39
Rubella (*see* Panencephalitis,
rubella)

S

Sacroiliitis, Jan. 24
grade IV with fusion, Jan. 25
Scanning: liver-spleen, Sept. 29
Schober test: in ankylosing
spondylitis, Jan. 23-24
Scintigraphy (*see* Myocardium,
scintigraphy)
Scintiscan (*see* Myocardium,
scintiscan)
Sclerosing (*see* Panencephalitis,
subacute sclerosing)
Sclerosis
amyotrophic lateral, possible
viral etiology, Aug. 67-68
multiple, possible viral etiology,
Aug. 66-67
Scrotum: infections of, Nov. 32
Sebaceous cyst: infected, Nov. 36
Septic abortion, Nov. 25-26
Shunting: intrahepatic, and
systemic clearance of
bacteria, Sept. 26-28
Sick sinus syndrome and variants,
Mar. 16-18
permanent pacing in,
indications, Mar. 18
Sinus
pilonidal, infected, Nov.
46-47
visceral sinus tract, infected,
Nov. 45-46
Sinusitis, Oct. 54-55
Skin
abscess, Nov. 37-39
anaerobes in, incidence of,
Nov. 38
infection of, Nov. 33-57
anaerobic, categories of, Nov.
34
cephalosporins in, July 48
ulcer, infected, Nov. 35-36

Sleep

apnea syndrome, May 6-24
acromegaly and, May 45-46
androgen excess and, May
46-47
appliances in, May 21
autonomic dysfunction and,
May 42
clinical presentation May 7-8
cordotomy and, May 43
drugs in, May 19-21
encephalitis and, May 44
endocrine disorders and, May
44-47
hypothyroidism and, May
44-45
kyphoscoliosis and, May
48-49
lung disease and, May 49-50
myotonic dystrophy and, May
43
neurologic diseases and, May
41-44
pathogenesis, May 10-11
pathophysiology, May 11-17
pharyngeal airway in, May 11
poliomyelitis and, May 42-43
polysomnography in, May 8-9
relationship with Pickwickian
syndrome, May 23-24
spine injury and, cervical,
May 43
stroke and, May 44
sudden infant death syndrome
and, May 50-52
surgery of, May 21-23
treatment, May 17-23
weight loss and, May 18-19
in asymptomatic subjects, May
25-30
epidemiology, May 25-27
gas exchange during, May 32
Snoring, May 28-29
as risk factor, May 29-30
Soft tissue infection
cephalosporins in, July 48
gas-forming, Nov. 56
synergistic, Nov. 27

Spine

"bamboo," in spondylitis, Jan. 14
cervical, injury, and sleep apnea
syndrome, May 43

Spleen

infections of, Nov. 16
-liver imaging, Sept. 29

Spondylarthritis: seronegative,
Jan. 10-17

Spondylitis

advanced, Jan. 14
ankylosing (*see below*)
lordosis in, normal lumbar,
"straightening" of, Jan.
13
"squaring" of vertebral bodies
in, Jan. 13

Spondylitis, ankylosing, Jan.
17-32

back pain in, five characteristics
of, Jan. 21
calcification at entheses in, Jan.
9

chest expansion in, Jan. 24-25
diagnosis, Jan. 20-26
exercise in, Jan. 28-29
Forestier's sign in, Jan. 25-26
fusion at entheses in, Jan. 9
history, clinical, Jan. 18-20
HLA-B27 test in, Jan. 22-23
management, Jan. 27-32
medical, Jan. 30-32

New York criteria for, Jan. 20
prevalence, Jan. 26-27
radiography of, Jan. 23
Schober test in, Jan. 23-24
signs, special clinical, Jan.
23-26

straight lower back in, Jan. 19
supportive therapy of, Jan.
29-30

Stenosis (*see* Coronary artery
stenosis)

Stomach

in anorexia nervosa, June 24
bypass, illustration, May 19
infections related to, Nov. 16
partition, illustration, May 19

Streptococcal myonecrosis:

anaerobic, Nov. 53-54

Stroke

dementia due to, Apr. 43-47
in sleep apnea syndrome, May
44

ST-segment depression: in exercise
stress ECG in men, Dec. 37

ST-segment response

to exercise as predictor of
coronary artery disease,
Dec. 32

relationship with exercise
capacity, Dec. 30-32

Subcutaneous abscess, Nov. 37-39
anaerobes in, incidence of, Nov.
38

Subcutaneous tissue infection,
Nov. 33-57

anaerobic, categories of, Nov. 34

Subdural empyema, Oct. 48

Subphrenic abscess, Nov. 8-9

Sudden infant death syndrome:

and sleep apnea, May 50-52

Sulfur colloid, Sept. 28

Surgical prophylaxis:

cephalosporins for, July
49-50

Susceptibility testing: and

anaerobic infection, Oct. 28

T

Tachycardia: pacemaker-mediated,
treatment by extension of
atrial refractory period,
Mar. 35

Taxonomy, Oct. 10-11

Technetium-99m sulfur colloid: for
liver-spleen imaging, Sept.
29

Tendon: Achilles, necrosis of, Nov.
33

Test

sensitivity, Dec. 8
specificity, Dec. 8

Tetanus, Nov. 82-88

clinical picture, Nov. 84-85

Tetanus (*cont.*)
 diagnosis, Nov. 85-86
 epidemiology, Nov. 83
 pathogenesis, Nov. 83-84
 prognosis, Nov. 87-88
 prophylaxis, Nov. 88
 guide to, Nov. 88
 therapy, Nov. 86-87
Tetracycline: in anaerobic infection, Oct. 32, 34
Thallium 201
 myocardial scintiscan, Dec. 29
 test performance during exercise, Dec. 29, 35
 scintigraphy (*see* Myocardium, 201)
Thyroid: in anorexia nervosa, June 21
Ticarcillin: in anaerobic infection, Oct. 31
Tomography: computed, of pharynx, May 12
Tonsil: peritonsillar abscess, Oct. 55-56
Toxic drug reactions
 to cephalosporins, July 51-52
 dementia syndrome due to, Apr. 52-53
Toxicity: of drugs active against anaerobic bacteria, Oct. 33
Trifascicular block: chronic, permanent pacing in, indications, Mar. 14
Tropical ulcer, Nov. 37

U

Ulcer
 decubitus, infected, Nov. 41-42
 Meleney's, Nov. 47
 skin, infected, Nov. 35-36
 tropical, Nov. 37
Urinary tract
 bacteremia related to, Nov. 30-31
 infection, Nov. 27-31
 anaerobes in voided urine, Nov. 28-30

cephalosporins in, July 46
 pathogenesis, Nov. 27-28

V

Vaginosis: anaerobic, Nov. 20-21
Vasopressin: in anorexia nervosa, June 23
Ventilators: in COPD, May 39
Ventricle
 intraventricular conduction abnormalities, chronic, permanent pacing in, Mar. 12-14
 pacing, Mar. 39-40
 hemodynamic comparison with atrial pacing, Mar. 28
 synchronized to atrial activity, Mar. 21
 repetitive response produced by committed DVI pacing, Mar. 32
Ventriculoatrial conduction: and pacemaker syndrome, Mar. 27-29
Vertebra: bodies, "squaring" in spondylitis, Jan. 13
Vessels
 in anorexia nervosa, June 23
 gangrene of, infected, Nov. 55
Vincent's angina, Oct. 55-56
Virus(es)
 antigens, changes in, Aug. 15-16
 conventional, properties of, Aug. 18-21
 defective interfering particles, Aug. 16-17
Echovirus (*see* Meningoencephalitis, Echovirus)
 in etiology of neurologic diseases, possible etiology, Aug. 66-68
 failure
 to express viral antigens on cell membranes, Aug. 16
 to release viral particles, Aug. 16

immunodeficiency and, Aug. 18
infection (*see below*)
measles, isolated from subacute
sclerosing panencephalitis,
Aug. 28-30
mutants, temperature-sensitive,
Aug. 17
rubella, isolates from
progressive rubella
panencephalitis, Aug. 35-36
unconventional
microbiology of, Aug. 61-64
properties of Aug. 18-21
Virus infection
acute, Aug. 7-15
pathogenesis within nervous
system, Aug. 13-14
cell-associated, Aug. 16-17
of central nervous system
invasion of central nervous
system, Aug. 10-13
pathogenesis, Aug. 7-18
slow virus diseases, Aug.
21-66

termination of, Aug. 14-15
transmission routes, Aug.
8-10
chronic
pathogenesis, Aug. 15-18
role of antibody in, Aug.
17-18
conventional, clinical syndromes
associated with, Aug. 22-48
unconventional, diseases
associated with, Aug.
48-59
Visceral sinus tract: infected, Nov.
45-46

W

Weight
gain after therapy in anorexia
nervosa, June 34
loss, and sleep apnea syndrome,
May 18-19
Wenckebach response: to
pacemaker, Mar. 37